Original from: bioM¨¦rieux
bioM¨¦rieux, a world leader in the field of in vitro diagnostics, announces the CE-marking of VIDAS® VITAMIN B12 TOTAL, an automated quantitative test for use on the VIDAS® immunoassay instruments, for the measurement of total Vitamin B12 concentration in human serum or plasma.
Vitamin B12, also known as cobalamin, is essential for well-being and cellular metabolism. This micronutrient, mainly present in food products from animal origin ¨C particularly meat, fish, eggs and dairy ¨C is required for normal functioning of the central nervous system, DNA synthesis and healthy red blood cell formation.
Measuring levels of vitamin B12 may help optimize patients¡¯ care since its deficiency can be associated with anemia or neurological symptoms including cognitive difficulties or impaired gait. VIDAS® VITAMIN B12 TOTAL is an automated quantitative test to aid in the assessment of vitamin B12 status in adults with suspected vitamin B12deficiency or at risk for low levels of vitamin B12.
This new assay is for use on all VIDAS® immunoanalysers that provide laboratory personnel with increased throughput and full traceability of test results. VIDAS® VITAMIN B12 TOTAL completes the VIDAS® routine test menu, reinforcing the family of assays targeting anemia.
¡°As it enters a fourth decade, VIDAS® remains a core focus of the bioM¨¦rieux immunoassay strategy with continued R&D investment in new product innovation. VIDAS® VITAMIN B12 TOTAL perfectly complements our comprehensive VIDAS® portfolio that also includes infectious diseases, emergency, and critical care assays. The launch of VIDAS® VITAMIN B12 TOTAL is a testament to bioM¨¦rieux¡¯s on-going commitment to provide value-add diagnostic solutions to lab and healthcare professionals for optimized patient care,¡± commented Jennifer Zinn, Executive Vice President, Clinical Operations, bioM¨¦rieux.
The commercial launch of VIDAS® VITAMIN B12 TOTAL is planned in select countries at the end of 2024, with an extended rollout in Q1 2025.
